Complete financial analysis of BioLargo, Inc. (BLGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLargo, Inc., a leading company in the Chemicals industry within the Basic Materials sector.
You may be interested
- Ultra Brands Ltd. (ULTA.CN) Income Statement Analysis – Financial Results
- Golden Independence Mining Corp. (GIDMF) Income Statement Analysis – Financial Results
- Eurocash S.A. (EUSHF) Income Statement Analysis – Financial Results
- ANYCOLOR Inc. (5032.T) Income Statement Analysis – Financial Results
- Enovix Corporation (ENVX) Income Statement Analysis – Financial Results
BioLargo, Inc. (BLGO)
About BioLargo, Inc.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | 1.36M | 516.21K | 281.11K | 127.58K | 111.55K | 167.95K | 65.54K | 156.19K | 156.76K | 138.13K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 749.84K | 833.54K | 1.88M | 2.39M | 1.93M | 2.50M | 1.30M | 4.50M | 7.70M | 9.40M | 9.80M | 6.70M |
| Cost of Revenue | 6.08M | 3.03M | 1.43M | 1.20M | 945.00K | 743.00K | 322.72K | 105.88K | 62.07K | 56.00K | 29.66K | 39.78K | 44.76K | 125.48K | 114.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.29K | 0.00 | 119.41K | 119.18K | 22.41K | 0.00 | 0.00 | 0.00 | 0.00 | 5.10M | 6.40M | 7.80M | 7.70M | 5.20M |
| Gross Profit | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | 621.00K | 193.50K | 175.23K | 65.52K | 55.55K | 138.29K | 25.76K | 111.43K | 31.28K | 23.58K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | -20.29K | 0.00 | 630.43K | 714.35K | 1.86M | 2.39M | 1.93M | 2.50M | 1.30M | -600.00K | 1.30M | 1.60M | 2.10M | 1.50M |
| Gross Profit Ratio | 50.32% | 48.56% | 43.58% | 50.49% | 49.22% | 45.53% | 37.48% | 62.34% | 51.35% | 49.80% | 82.34% | 39.30% | 71.34% | 19.95% | 17.07% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.08% | 85.70% | 98.81% | 100.00% | 100.00% | 100.00% | 100.00% | -13.33% | 16.88% | 17.02% | 21.43% | 22.39% |
| Research & Development | 2.28M | 1.32M | 1.37M | 1.34M | 1.47M | 1.72M | 1.63M | 1.38M | 684.55K | 642.92K | 742.25K | 126.02K | 99.50K | 100.56K | 170.12K | 113.75K | 131.35K | 129.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 6.14M | 5.26M | 4.43M | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 246.00K | 246.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.06M | 6.73M | 6.17M | 7.47M | 6.14M | 5.26M | 4.43M | 3.71M | 3.55M | 2.79M | 2.00M | 4.61M | 3.17M | 4.12M | 3.96M | 4.83M | 2.99M | 1.63M | 944.81K | 971.94K | 2.34M | 2.16M | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -74.00K | -55.00K | -137.00K | -218.00K | 73.00K | 71.13K | 13.74K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | 0.00 | 0.00 | 0.00 | 8.55K | -661.87K | 3.45M | 268.46K | -1.32M | 258.13K | 186.53K | 189.35K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.34M | 7.98M | 7.48M | 8.67M | 7.39M | 6.88M | 6.09M | 5.11M | 4.25M | 3.45M | 2.76M | 4.74M | 3.27M | 4.23M | 5.25M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.35M | 1.50M | 7.42M | 2.86M | 453.95K | 1.99M | 1.87M | 1.57M | 1.20M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Cost & Expenses | 16.42M | 11.00M | 8.91M | 9.88M | 8.34M | 7.62M | 6.41M | 5.22M | 4.31M | 3.50M | 2.79M | 4.78M | 3.32M | 4.36M | 5.36M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.37M | 1.50M | 7.54M | 2.98M | 476.36K | 1.99M | 1.87M | 1.57M | 1.20M | 6.50M | 8.00M | 9.40M | 8.80M | 5.70M |
| Interest Income | 0.00 | 53.00K | 234.00K | 1.92M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.53K | 35.96K | 0.00 | 153.51K | 0.00 | 255.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 91.00K | 53.00K | 234.00K | 1.92M | 4.00M | 3.49M | 3.86M | 3.13M | 994.67K | 348.15K | 281.59K | 616.35K | 793.26K | 1.67M | 1.63M | 1.15M | 1.56M | 344.88K | 242.49K | 250.70K | 344.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 45.00K | 20.00K | 58.00K | 65.00K | 50.00K | 29.84K | 15.89K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | -796.55K | 246.10K | -4.60K | 660.30K | 9.94K | 176.10K | 268.46K | 197.19K | 258.13K | 186.53K | 189.35K | -100.00K | -300.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | -7.23M | -5.73M | -4.93M | -4.07M | -3.38M | -2.61M | -4.71M | -3.15M | -4.19M | -4.11M | -5.00M | -3.05M | -2.56M | -698.70K | -967.34K | -1.71M | -1.54M | -2.77M | -4.46M | 1.60M | 664.46K | 245.16K | 1.12M | -100.00K | -2.30M | -400.00K | -200.00K | 1.00M | 1.00M |
| EBITDA Ratio | -34.23% | -85.16% | -248.83% | -299.22% | -341.21% | -449.49% | -1,136.19% | -1,749.86% | -3,346.62% | -3,030.56% | -1,553.32% | -7,189.59% | -2,018.88% | -2,751.20% | 3,370.18% | 0.00% | -3,918.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.77% | -225.65% | 246.39% | 27.78% | 12.68% | 44.96% | -7.69% | -51.11% | -5.19% | -2.13% | 10.20% | 14.93% |
| Operating Income | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | -6.41M | -5.90M | -4.93M | -4.18M | -3.39M | -2.62M | -4.72M | -3.16M | -4.20M | -14.01M | -6.05M | -3.78M | -1.76M | -944.81K | -971.94K | -2.37M | -1.50M | -6.79M | -2.15M | -112.29K | 406.32K | 58.63K | 935.07K | 100.00K | -2.00M | -300.00K | -200.00K | 1.00M | 1.00M |
| Operating Income Ratio | -34.23% | -87.00% | -252.11% | -306.17% | -348.09% | -470.09% | -1,141.98% | -1,755.52% | -3,277.49% | -3,040.35% | -1,559.82% | -7,197.88% | -2,023.91% | -2,678.33% | -10,138.78% | 0.00% | -4,730.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -905.25% | -257.85% | -5.98% | 16.99% | 3.03% | 37.39% | 7.69% | -44.44% | -3.90% | -2.13% | 10.20% | 14.93% |
| Total Other Income/Expenses | -449.00K | 61.00K | -458.00K | -2.12M | -4.74M | -4.28M | -3.65M | -3.14M | -895.55K | -348.15K | -281.59K | -616.35K | -793.26K | -1.54M | -8.76M | 59.99K | -1.48M | 796.55K | -246.10K | -246.10K | -344.83K | 6.74K | 121.94K | 35.96K | -1.41M | 153.51K | 222.88K | 255.93K | 200.00K | 200.00K | 100.00K | 300.00K | 0.00 | -1.00M |
| Income Before Tax | -4.64M | -5.13M | -6.89M | -9.70M | -11.44M | -10.70M | -9.55M | -8.07M | -5.08M | -3.74M | -2.90M | -5.33M | 0.00 | -4.07M | -22.77M | -5.99M | -5.26M | -965.82K | -1.19M | -1.22M | -2.71M | -1.49M | -6.65M | -2.11M | -1.52M | 559.83K | 281.51K | 1.19M | 300.00K | -1.80M | -200.00K | 300.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | -37.90% | -87.22% | -272.38% | -398.85% | -614.72% | -784.16% | -1,849.34% | -2,872.35% | -3,979.42% | -3,352.46% | -1,727.49% | -8,138.27% | 0.00% | -2,599.36% | -16,482.26% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.54% | -80.78% | 23.40% | 14.56% | 47.62% | 23.08% | -40.00% | -2.60% | 3.19% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | -636.00K | 483.00K | 766.00K | 3.31M | -790.00K | 3.43M | 2.89M | 874.50K | -47.45K | -372.92K | 0.00 | 793.26K | 1.54M | 10.39M | 1.09M | 1.48M | 344.88K | -3.61K | 250.70K | 4.91M | 3.44M | 0.00 | 3.47K | -11.54K | 196.71K | 103.68K | 554.64K | -100.00K | -100.00K | -100.00K | 100.00K | -1.00M | -900.00K |
| Net Income | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M | -10.22M | -9.12M | -7.84M | -5.06M | -3.69M | -2.53M | -5.33M | -3.95M | -5.74M | -15.61M | -7.14M | -5.26M | -1.31M | -1.19M | -1.22M | -7.62M | -4.94M | -6.65M | -2.12M | -1.51M | 531.12K | 261.83K | 968.36K | -300.00K | -1.70M | -100.00K | 200.00K | 1.00M | 900.00K |
| Net Income Ratio | -28.65% | -76.41% | -291.47% | -430.35% | -792.53% | -749.34% | -1,766.19% | -2,788.89% | -3,962.92% | -3,309.92% | -1,505.44% | -8,138.27% | -2,531.80% | -3,663.12% | -11,302.54% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.96% | -80.16% | 22.20% | 13.54% | 38.72% | -23.08% | -37.78% | -1.30% | 2.13% | 10.20% | 13.43% |
| EPS | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| Weighted Avg Shares Out | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
| Weighted Avg Shares Out (Dil) | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
BioLargo Inc announces it achieved record 1Q revenue as its subsidiary ONM Environmental reports its first profitable quarter
BioLargo Inc (OTCQB:BLGO) has reported record revenue in its first quarter results as the company solidifies its reputation as a trusted and credible provider of cleantech solutions. For the three months ending March 31, 2022, the company reported company-wide revenue of...
BioLargo sees preliminary 1Q revenue jump by 60% thanks to ONM Environmental and its engineering division
BioLargo Inc (OTCQB:BLGO). said it broke its own quarterly revenue record in the first quarter, posting a 60% jump year-over-year on the back of strong contributions from its subsidiary ONM Environmental and its engineering division.
BioLargo, Inc. (BLGO) CEO Dennis Calvert on Q4 2021 Results - Earnings Call Transcript
BioLargo, Inc. (BLGO) CEO Dennis Calvert on Q4 2021 Results - Earnings Call Transcript
BioLargo Annual Earnings Results Webcast and Conference Call Monday, April 4, 2022 - 4:30 PM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / April 1, 2022 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will host an investor webcast and conference call on Monday April 4, 2022, at 1:30 pm PT /...
BioLargo says 2021 revenue increased year-over-year as its cleantech and engineering solutions advanced
BioLargo Inc (OTCQB:BLGO) said 2021 revenue increased by single digits year-over-year as the company advanced its cleantech and engineering solutions. Consolidated revenue for the year ended December 31, 2021, was $2,531,000, which was a 4% increase over 2020.
BioLargo says its three current projects are 'major growth catalysts'
BioLargo Inc (OTCQB:BLGO) said that its current projects are “major growth catalysts,” as it shared updates on its three key projects with investors. "These initiatives are still unfolding, and in some cases, such as with PFAS testing on behalf of...
BioLargo says its Aqueous Electrostatic Concentrator eliminates multiple PFAS compounds in testing with client water
BioLargo Inc (OTCQB:BLGO) announced that its Aqueous Electrostatic Concentrator (AEC) has been proven to eliminate multiple per- and polyfluoroalkyl substance (PFAS) compounds from water provided by a large municipality in Southern California. Man-made PFAS chemicals generated by industrial operations are resistant...
BioLargo begins next step in preparing Garratt-Callahan minimal liquid discharge system for commercial launch
BioLargo Inc (OTCQB:BLGO) said it has taken the next step to commercialize a new wastewater treatment technology called the "minimal liquid discharge" system, which it designed and manufactured for Garratt-Callahan, a century-old national water treatment company. At this stage, the company said its...
BioLargo signs manufacturer's representative agreement with ICS for its water treatment technologies
BioLargo Inc made an important move towards building a commercial network for its sale and distribution as it signed a manufacturer's representative agreement with ICS Group— a premier manufacturer's representative company that has provided innovative wastewater, energy management, and renewable energy...
BioLargo inks strategic partnership with Ikigai Holdings to launch its new pet odor control product, POOPH
BioLargo Inc announced that it has received a "go decision" from its strategic partner, Ikigai Holdings LLC, following positive results from the test-marketing phase of a new pet odor control product based on BioLargo's proprietary technology, branded POOPH. Westminster, California-based...
Source: https://incomestatements.info
Category: Stock Reports